Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Last trade$2.95
Day change+$0.07 (+2.43%)
Day range$2.85 – $2.99
Volume476,084
Market cap$56M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$55.96M
Price / earnings
—
Price / book
0.28×
Price / sales
1.3×
EV / sales
-2.48×
EV / EBITDA
0.58×
Profitability
Earnings per share
-$9.31
Return on assets
-74.66%
Return on equity
-90.73%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.57×
Quick ratio
4.47×
Cash ratio
3.87×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$170.04M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TNXP, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$17.23M
$13.54M
$6.88M
$5.39M
$3.29M
$2M
$2.43M
$2.58M
Cost of revenue
$1.25M
$703K
$1.58M
$1.06M
$1.37M
$3.27M
$943K
$1.18M
Gross profit
$15.98M
$12.84M
$5.3M
$4.33M
$1.92M
-$1.27M
$1.49M
$1.4M
Selling, general and administrative
$45.59M
$35.96M
$28.62M
$35.68M
$25.7M
$16.2M
$10.1M
$15.58M
Research and development
$25.82M
$19.42M
$18.21M
$16.94M
$9.29M
$10.82M
$7.44M
$8.3M
Total operating expenses
$71.41M
$55.38M
$46.84M
$52.62M
$34.99M
$27.02M
$17.54M
$23.88M
Operating income
-$55.43M
-$42.54M
-$41.54M
-$48.29M
-$33.07M
-$28.3M
-$16.05M
-$22.48M
Interest expense
$1.36M
$1.43M
$0
$0
$1.23M
$943K
$0
-$280K
Income before taxes
-$53.33M
-$40.55M
-$40.19M
-$46.91M
-$32.01M
-$28.27M
-$16.83M
-$22.11M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$53.33M
-$40.55M
-$40.19M
-$46.91M
-$32.01M
-$28.27M
-$16.83M
-$22.11M
Net income attributable to common shareholders
-$53.33M
-$40.55M
-$40.19M
-$46.91M
-$32.01M
-$28.27M
-$16.83M
-$22.11M
EBITDA
-$54.79M
-$41.92M
-$40.98M
-$47.8M
-$32.61M
-$27.81M
-$15.56M
-$21.98M
Basic earnings per share
-$2.89
-$2.44
-$2.93
-$3.95
-$3.59
-$3.86
-$2.84
-$9.83
Diluted earnings per share
-$2.89
-$2.44
-$2.93
-$3.95
-$3.59
-$3.86
-$2.84
-$9.83
Recent news
Company coverage with links to the original publishers.
Tonix Pharmaceuticals announced a second commercial payer agreement with a leading GPO effective June 1, 2026, providing coverage for TONMYA® to approximately 17 million additional U.S. commercial lives. Combined with the first agreement announced in May 2026, TONMYA now has commercial coverage for approximately 52 million U.S. lives (29% of total commercial lives). TONMYA is the first new fibromyalgia medicine approved by the FDA in over 15 years and is also available under Medicaid in most states covering approximately 75 million lives.
Bay Area Lyme Foundation raised $900,000 at its annual LymeAid 2026 gala, featuring entertainment by Dana Carvey and Chris Isaak. The foundation presented its inaugural Neil L. Spector, MD, Legacy Award to Timothy Haystead, PhD, and distributed $300,000 in Emerging Leader Awards to researchers studying Lyme disease diagnostics and tick-borne infections. Bay Area Lyme Ventures expanded its portfolio with a new investment in Galaxy Diagnostics.
Tonix Pharmaceuticals announced a poster presentation at ISPOR 2026 featuring a retrospective U.S. real-world claims analysis of fibromyalgia patients using data from April 2021-April 2024. TONMYA (cyclobenzaprine HCl sublingual tablets), approved by the FDA on August 15, 2025, and commercially launched on November 17, 2025, is the first new prescription medicine for fibromyalgia in over 15 years. The company also reported strong Q1 2026 results with 2,145 healthcare providers prescribing TONMYA, 3,588 patients initiated treatment, and approximately 5,400 prescriptions filled.
Tonix Pharmaceuticals announced the publication of pharmacokinetic data for TONMYA (cyclobenzaprine HCl sublingual tablets) in the peer-reviewed journal Clinical Pharmacology in Drug Development. The study demonstrated that TONMYA, the first new FDA-approved fibromyalgia treatment in over 15 years (approved August 2025, commercially launched November 2025), achieved steady-state pharmacokinetics at Day 20 with rapid absorption and higher bioavailability per dose compared to oral extended-release cyclobenzaprine. The sublingual formulation was generally safe and well-tolerated with no serious adverse events.
Tonix Pharmaceuticals announced that CEO Seth Lederman will deliver a company presentation at BIO-Europe Spring 2026 in Lisbon on March 24, 2026. The presentation will highlight the company's commercial-stage biotechnology portfolio focused on CNS and immunology treatments, including TONMYA® for fibromyalgia (launched November 2025 with over 1,500 prescriptions), acute migraine products, and pipeline candidates in development.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.